ReviewPharmacoEconomics1998
Cost-of-illness studies. Useful for health policy?
Review in PharmacoEconomics, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global and Regional Economic Burden of Eating Disorders: A Systematic Review and Critique of Methods.The International journal of eating disorders · 2025Pooled it
- The excess costs of depression: a systematic review and meta-analysis.Epidemiology and psychiatric sciences · 2019Pooled it
- International comparison of cost of falls in older adults living in the community: a systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010Pooled it
- Effectiveness of eletriptan in reducing time loss caused by migraine attacks.PharmacoEconomics · 2000Trial
- Estimating the economic and societal burden of suicide and suicide attempts in India: a study protocol.BMJ open · 2025Article
- Economic Burden and Healthcare Trajectories of Patients Awaiting Heart Transplantation in a French Tertiary Center.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- The Economic Impact of Post-Traumatic Stress Disorder Among Patients with Systemic Autoimmune Diseases During the COVID-19 Pandemic.International journal of environmental research and public health · 2024Article
- The societal economic impact of vision impairment in adults 40 years and above: findings from the National Eye Survey of Trinidad and Tobago.Eye (London, England) · 2024Article
- The True Price of External Health Effects from Food Consumption.Nutrients · 2023Article
- Expert opinion on a consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies: qualitative interviews.International journal of technology assessment in health care · 2023Article
- The economics of vision impairment and its leading causes: A systematic review.EClinicalMedicine · 2022Review
- Estimating the global cost of vision impairment and its major causes: protocol for a systematic review.BMJ open · 2020Article
- Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.BMC public health · 2020Article
- The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study.BMC public health · 2017Article
- Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?PharmacoEconomics · 2016Article
- The burden of disease in rheumatoid arthritis.PharmacoEconomics · 2014Article
- Societal costs of non-cardiac chest pain compared with ischemic heart disease--a longitudinal study.BMC health services research · 2013Article
- Economic burden of acute coronary syndrome in South Korea: a national survey.BMC cardiovascular disorders · 2013Article
- A cost-of-illness study of spina bifida in Italy.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Methodological considerations in cost of illness studies on Alzheimer disease.Health economics review · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A sample of cost-of-illness (COI) studies was reviewed, which included studies for specific diseases ('specific' studies) as well as those for the entire range of diseases ('general' studies). Theoretically, COI studies may deliver suitable information for health policy and rational healthcare spending. In practice, however, the informative value of 'specific' prevalence-based COI studies is very limited. A static picture of costs is presented in these studies, as trends in costs are not being described or explained by factors such as demography, epidemiology and technology. No practical link is offered between COI estimates and economic evaluation. Incidence-based COI studies can provide more relevant information for economic evaluation studies. It appears more useful to perform general COI studies, as these provide comparable estimates of disease costs and put cost estimates in a total healthcare perspective. Compared with specific COI studies, general COI studies better facilitate the analysis and projection of trends in costs, for example due to aging.
Indexed as
Identifiers
10186453What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.